Shopping Cart
- Remove All
- Your shopping cart is currently empty
Zharp2-1, a RIPK2 inhibitor, inhibits the transcription of inflammatory cytokines induced by MDP-induced or Listeria monocytogenes infection and alleviates MDP-induced peritonitis symptoms in mice, which can be used for the study of inflammatory bowel disease (IBD).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | $62 | In Stock | |
10 mg | $98 | In Stock | |
25 mg | $196 | In Stock | |
50 mg | $322 | In Stock | |
100 mg | $513 | In Stock |
Description | Zharp2-1, a RIPK2 inhibitor, inhibits the transcription of inflammatory cytokines induced by MDP-induced or Listeria monocytogenes infection and alleviates MDP-induced peritonitis symptoms in mice, which can be used for the study of inflammatory bowel disease (IBD). |
In vitro | iBMDM from mice were stimulated with 10 ng/mL IFN-γ and pre-treated with Zharp2-1 (IC50=6.4-17.4 nM) for 2 hours, followed by stimulation with 10 μg/mL MDP or 1 μg/mL L18-MDP for 12 hours. The results indicate that Zharp2-1 effectively blocks cytokine transcription and release in human and murine cells induced by MDP. [1]. |
In vivo | Treatment with Zharp2-1 (15 mg/kg, oral gavage, once daily, for 6 days) protects rats from DNBS-induced colon shortening and colon weight gain, indicating that Zharp2-1 therapy significantly improves colonic mucosal structural damage, muscle thickening, and inflammatory infiltration[1]. |
Molecular Weight | 383.4 |
Formula | C19H18N3O2PS |
Cas No. | 2772600-18-5 |
Smiles | O=P(C1=CC=2C(=NC=CC2NC=3C=CC=4SC=NC4C3)C=C1OC)(C)C |
Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||
Solubility Information | DMSO: 2 mg/mL (5.22 mM), Sonication is recommended. | |||||||||||||||
Solution Preparation Table | ||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.